View in EDS

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.

Saved in:
Bibliographic Details
Title: Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
Authors: Parry CW; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Pellicano F; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Schüttelkopf AW; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Beyer KS; Novartis Institute for BioMedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056 Basel, Switzerland., Bower J; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Bryson A; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Cameron K; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Cerutti NM; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Clark JP; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Davidson SC; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Davies K; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Drysdale MJ; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Engelman J; Novartis Institutes for BioMedical Research, Inc., 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States., Estevan-Barber A; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Gohlke A; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Gray CH; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Guthy DA; Novartis Institute for BioMedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056 Basel, Switzerland., Hong M; NCI RAS Initiative, Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, Maryland 21702, United States., Hopkins A; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Hutchinson LD; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Konczal J; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Maira M; Novartis Institute for BioMedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056 Basel, Switzerland., McArthur D; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Mezna M; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., McKinnon H; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Nepravishta R; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Ostermann N; Novartis Institute for BioMedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056 Basel, Switzerland., Pasquali CC; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Pollock K; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Pugliese A; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Rooney N; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Schmiedeberg N; Novartis Institute for BioMedical Research, Fabrikstrasse 2, Novartis Campus, CH-4056 Basel, Switzerland., Shaw P; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Velez-Vega C; Novartis Institutes for BioMedical Research, Inc., 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States., West C; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., West R; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K., Zecri F; Novartis Institutes for BioMedical Research, Inc., 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States., Taylor JB; Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD, U.K.
Source: Journal of medicinal chemistry [J Med Chem] 2025 May 08; Vol. 68 (9), pp. 9129-9161. Date of Electronic Publication: 2025 Mar 31.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4804
DOI:10.1021/acs.jmedchem.4c02929